| WB | 1/500-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | MEC, CCK1, SCYA28 |
| WB Predicted band size | 14 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human CCL28 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CCL28抗体的3篇参考文献示例(文献信息为模拟，仅供参考)：
---
1. **标题**: *CCL28 regulates mucosal immunity via IgA antibody transport in the gut*
**作者**: Smith A, et al.
**摘要**: 研究通过抗CCL28抗体阻断小鼠肠道CCL28信号，发现其显著抑制IgA浆细胞向肠黏膜的迁移，揭示了CCL28在黏膜免疫中调控抗体运输的关键作用。
2. **标题**: *Anti-CCL28 monoclonal antibody attenuates allergic airway inflammation in a murine model*
**作者**: Chen L, et al.
**摘要**: 开发了一种特异性抗CCL28单克隆抗体，并在哮喘模型中验证其效果。结果显示，抗体通过抑制CCL28介导的嗜酸性粒细胞趋化，显著减轻气道炎症反应。
3. **标题**: *CCL28 chemokine and its receptor CCR10 in colorectal cancer progression*
**作者**: Wang Y, et al.
**摘要**: 利用抗CCL28抗体研究其在结直肠癌中的作用，发现CCL28高表达与肿瘤侵袭性相关，抗体阻断可减少肿瘤细胞迁移及血管生成，提示其作为潜在治疗靶点。
---
(注：以上文献为示例，实际引用需以真实出版物为准。建议通过PubMed或Web of Science等平台检索具体文献。)
CCL28. a member of the CC chemokine family, is a small secreted protein that binds to two receptors: CCR10 and CCR3. Primarily expressed in mucosal tissues such as the gastrointestinal tract, respiratory epithelium, and mammary glands, it plays a critical role in regulating immune responses, particularly in mucosal immunity. CCL28 facilitates the recruitment of IgA antibody-secreting cells (ASCs) and CCR10/CCR3-expressing lymphocytes to mucosal sites, thereby maintaining immune homeostasis and defending against pathogens. Its expression is modulated by inflammatory cytokines, microbial exposure, and tissue-specific factors, linking it to both physiological immune surveillance and pathological conditions.
Antibodies targeting CCL28 are essential tools for studying its biological functions, localization, and interaction networks. They are widely used in immunoassays (e.g., ELISA, Western blot), immunohistochemistry, and flow cytometry to quantify CCL28 levels in research models or clinical samples. In disease contexts, CCL28 antibodies help investigate its role in inflammatory bowel disease (IBD), cancer (e.g., colorectal carcinoma), and mucosal infections. Dysregulated CCL28 signaling has been implicated in chronic inflammation, tumor progression, and impaired mucosal defense, making it a potential therapeutic target. Neutralizing antibodies are also explored for blocking CCL28-mediated pathways in autoimmune disorders or enhancing mucosal vaccine efficacy.
Research on CCL28 antibodies continues to expand, driven by their diagnostic and therapeutic potential in mucosal immunity-related diseases.
×
